Seroatlas · Human Serome Atlas

LILRA1

Leukocyte immunoglobulin-like receptor subfamily A member 1

Also known as: CD85i, LIR-6, LIR6, LIRA1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O75019
Gene: LILRA1
Ensembl: ENSG00000104974
Chromosome: 19
Canonical length: 489 aa
Protein class: CD markers, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes an activating member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein is predominantly expressed in B cells, interacts with major histocompatibility complex class I ligands, and contributes to the regulation of immune responses. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, May 2013]

Canonical amino-acid sequenceUniProt

489 residues, UniProt reviewed canonical sequence.

>O75019|LILRA1
     1  MTPIVTVLIC LRLSLGPRTH VQAGTLPKPT LWAEPGSVIT QGSPVTLWCQ GILETQEYRL
    61  YREKKTAPWI TRIPQEIVKK GQFPIPSITW EHTGRYRCFY GSHTAGWSEP SDPLELVVTG
   121  AYIKPTLSAL PSPVVTSGGN VTLHCVSQVA FGSFILCKEG EDEHPQCLNS QPRTHGWSRA
   181  IFSVGPVSPS RRWSYRCYAY DSNSPHVWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPGE
   241  SLTLQCVSDV SYDRFVLYKE GERDFLQLPG PQPQAGLSQA NFTLGPVSRS YGGQYRCSGA
   301  YNLSSEWSAP SDPLDILIAG QFRGRPFISV HPGPTVASGE NVTLLCQSWG PFHTFLLTKA
   361  GAADAPLRLR SIHEYPKYQA EFPMSPVTSA HSGTYRCYGS LSSNPYLLSH PSDSLELMVS
   421  GAAETLSPPQ NKSDSKAGAA NTLSPSQNKT ASHPQDYTVE NLIRMGIAGL VLVVLGILLF
   481  EAQHSQRSL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LILRA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 13 nTPM

Expression across tissuesHPA

Tissue

spleen: 13 nTPM
appendix: 7.8 nTPM
bone marrow: 2.5 nTPM
lung: 2.1 nTPM
urinary bladder: 2 nTPM
spinal cord: 1.4 nTPM

Single-cell type

microglia: 16 nCPM
monocytes: 11 nCPM
kupffer cells: 5.1 nCPM
neutrophils: 4.3 nCPM
macrophages: 2.9 nCPM
cdc: 1.9 nCPM

Immune cell

non-classical monocyte: 170 nTPM
intermediate monocyte: 127 nTPM
classical monocyte: 47 nTPM
eosinophil: 36 nTPM
neutrophil: 36 nTPM
myeloid DC: 33 nTPM

Brain region

white matter: 2.7 nTPM
medulla oblongata: 2.1 nTPM
spinal cord: 2 nTPM
thalamus: 1.8 nTPM
midbrain: 1.6 nTPM
pons: 1.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.61
gnomAD pLI: 0
gnomAD missense Z: -2.17
DepMap mean gene effect: 0.1
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LILRA1 as an antibody target. Whether an autoantibody or antibody against LILRA1 could matter depends on whether native LILRA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LILRA1 is annotated at the cell surface, where native LILRA1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LILRA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...